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MaOBJECTIVES This study sought to investigate the prevalence of abnormal von Willebrand multimers (AbM) in patients
undergoing transcatheter aortic valve replacement (TAVR) and the impact of TAVR on the underlying factor variances.
BACKGROUND An association between the acquired von Willebrand syndrome (aVWS) and valvular aortic stenosis (AS)
has been established in the past and surgical aortic valve replacement (SAVR) shown to lead to factor recovery.
Prevalence and course of AbM in patients treated with TAVR though has not yet been described comprehensively.
METHODS Ninety-ﬁve consecutive patients underwent TAVR at our institution. Hemostaseologic testing was performed
before and up to 1 week after TAVR. Transvalvular and right heart hemodynamics as well as bleeding episodes were
recorded and analyzed with descriptive statistics.
RESULTS Baseline prevalence of AbM was 42% with an average high-molecular-weight multimer (HMWM) count of
16.2  3.3%. Pressure gradients correlated signiﬁcantly with the extent of HMWM deﬁciency (r ¼ –0.63 [p < 0.0001]).
Following valve implantation, HMWM increased proportional to the drop in mean pressure gradient and normalized in
most of the patients. However, residual aortic regurgitation/leakage led to inferior HMWM recovery but prosthesis-
patient mismatch (PPM) was rare and left HMWM uninﬂuenced. We saw no association of transfusion with AbM and
1-year mortality was unaffected by AbM.
CONCLUSIONS AbM in patients with AS undergoing TAVR is frequent. However, TAVR is capable of correcting AbM
and therefore possibly aVWS in patients with AS. As opposed to SAVR, bleeding and transfusion requirement in TAVR
patients was not associated with severe HMWM deﬁciency; PPM was rare and HMWM were uninﬂuenced by the proce-
dure. Aortic regurgitation after TAVR adversely inﬂuenced HMWM recovery. (J Am Coll Cardiol Intv 2015;8:692–700)
© 2015 by the American College of Cardiology Foundation.A side from the primary repercussions of aorticstenosis (AS), shear stress gives rise to hemo-staseologic alterations subsequently leading
to an acquired von Willebrand syndrome (aVWS) (1).
Gastrointestinal bleeding can be a clinical companion
and forms Heyde’s syndrome (2,3). A common el-
ement of aVWS is a diminished von Willebrand factor
(VWF), altered structure and/or limited function
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AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
AS = aortic stenosis
aVWS = acquired von
Willebrand syndrome
dPmean = mean transvalvular
gradient
HMWM = high-molecular-
weight multimer
LVESP = left ventricular end-
systolic pressure
PCWP = pulmonary capillary
wedge pressure
PPM = prosthesis-patient
mismatch
PVL = paravalvular leak
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693decreased content of the high-molecular-weight mul-
timers (HMWM) and severity of the AS, along with a
correction of the multimer content 1 day after SAVR
(6,7) was described. Currently transcatheter aortic
valve replacement (TAVR) is an alternative to SAVR
for selected patients (8) with superior outcomes in
speciﬁed populations (9). Nevertheless, the inﬂuence
on a shear stress–induced loss of HMWM in patients
undergoing TAVR has not been investigated compre-
hensively. However, greater age, multimorbidity, and
the necessity of dual antiplatelet therapy possibly
leading to a substantial increase in bleeding risk are
characteristic of patients envisaged for TAVR (10).
Hence, a comprehensive understanding of the preva-
lence and the impact of TAVR on the hemostaseologic
peculiarities in this population was the aim of the pre-
sent work.SEE PAGE 701
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
= von Willebrand factorMETHODS
STUDY DESIGN AND PATIENT POPULATION. Between
November 2011 and June 2013, a total of 95 patients
with severe AS underwent a transfemoral TAVR at our
institution. Written informed consent was obtained
and the registry was approved by the local ethics
committee. Exclusion criteria for participation were
to be within 1 month of resuscitation, systemic shock,
transfusion of fresh frozen plasma/factor concen-
trates and patients treated by left ventricular assist
devices. All data were prospectively collected as a
single-center registry. Inclusion criterion was native
AS with an aortic valve area #1.0 cm2 (#0.6 cm2/m2)
as determined by echocardiography. The individual
baseline risk of the patients was estimated by the
logistic EuroSCORE.
DEVICE DESCRIPTION AND PROCEDURE. Transcatheter
heart valves such as the Medtronic CoreValve (CV
Luxembourg, S.a.r.l.) (n ¼ 31), the Edwards Sapien
XT valve (Edwards Lifesciences, Irvine, California)
(n ¼ 51), the Edwards Centera valve (n ¼ 13) and St.
Jude Portico valve (St. Jude Medical, St. Paul, Min-
nesota) (n ¼ 1) were used as previously described
(11–14). After valve deployment, the ﬁnal transval-
vular gradient was measured invasively (i.e., simul-
taneous recording with a pigtail in the left ventricle
and a second pigtail in the ascending aorta) and a
standardized root angiography (30 cc/ 15 cc/s) was
performed to assess the extent of aortic regurgitation.
All patients received acetylsalicylic acid 100 mg,
before the procedure and continued indeﬁnitely.
A 600 mg loading dose of clopidogrel was adminis-
tered the day before the procedure, followed by 75 mgdaily for 3 months (Medtronic CoreValve) or 4
weeks (Edwards Sapien XT valve and
Edwards Centera valve), respectively. During
the intervention, 100 international units/kg
of unfractionated heparin were administered
to achieve an activated clotting time of 250 to
300 s. All procedures were performed under
analgosedation.
ECHOCARDIOGRAPHY, ROUTINE LABORATORY
DATA, AND FOLLOW-UP. A transthoracic and
transesophageal echocardiographic study
from all patients was obtained before and
after implantation of the transcatheter heart
valve. Transvalvular pressure gradients in-
cludingmean transvalvular gradient (dPmean)
were calculated with the modiﬁed Bernoulli
equation, aortic oriﬁce area was calculated
with the continuity equation and indexed to
the patient’s body surface area (15). Left
ventricular ejection fraction as well as the
grade of mitral and tricuspid regurgitation
were estimated by echocardiography before TAVR
and after. Moreover, creatinine, glomerular ﬁltration
rate, andmortality were determined.
INVASIVE HEMODYNAMIC DATA. Quantiﬁcation of
the AS was performed utilizing combined left and
right heart catheterization (7-F Swan-Ganz cath-
eter; Edwards Lifesciences, Irvine, California) before
and after TAVR. Right atrial pressure; pulmonary ar-
tery systolic, diastolic, and mean pressures; mean
aortic pressure; left ventricular end-systolic pressure
(LVESP) and end-diastolic pressure; and pulmonary
capillary wedge pressure (PCWP) were recorded. Car-
diac output (CO), cardiac index, stroke volume, stroke
volume index, systemic vascular resistance, systemic
vascular resistance index, pulmonary vascular resis-
tance, and pulmonary vascular resistance index, were
determined using the thermodilutionmethod. Finally,
the aortic valve area using the Gorlin formula (15,16)
and the valvuloarterial impedance (Zva), the sys-
temic arterial compliance (SAC) (17), and the
transpulmonary gradient were calculated immedi-
ately before and after TAVR.
DATA COLLECTION AND DEFINITIONS. All baseline
and follow-up variables were recorded and entered
into a database. Technical success was deﬁned as
stable device placement and function as assessed
by angiography and echocardiography. Device success
was deﬁned according to Valve Academic Research
Consortium-2 (VARC-2) (18). Invasive hemodynamic
data were obtained before and after TAVR (see pre-
vious text). N-terminal pro–B-type natriuretic peptide
VWF
TABLE 1 Demographics, Comorbidities, and Baseline Data
Total
(n ¼ 95)
NM
(n ¼ 55)
AbM
(n ¼ 40) p Values
Demographic data
Male 36 (37) 24 (43) 12 (30) 0.20
Age 82.4  6.5 81.8  6.9 83.3  6.1 0.29
EuroSCORE, % 21.7  18.3 23.1  18.1 19.9  18.6 0.44
Arterial hypertension 89 (93) 52 (94) 37 (92) 0.69
Coronary artery disease 55 (57) 35 (63) 20 (50) 0.21
Previous cardiac surgery 11 (11) 7 (12) 4 (10) 0.75
Chronic kidney disease 34 (35) 17 (30) 17 (42) 0.28
Diabetes mellitus 32 (33) 17 (30) 15 (37) 0.51
Atrial ﬁbrillation 43 (45) 25 (45) 18 (45) 1.0
History of bleeding 18 (20) 10 (18) 8 (20) 1.0
History of GI bleeding 11 (11) 7 (13) 4 (10) 0.75
History of stroke 11 (11) 9 (16) 2 (5) 0.11
TTE 1. 2. 3. 4.
LVEF, % 54.9  11.2 54.4  11.3 55.6  11.1 0.59
Aortic regurgitation $2 14 (15) 6 (10) 8 (20) 0.25
Mitral regurgitation $2 45 (47) 24 (43) 21 (52) 0.41
Tricuspid regurgitation $2 30 (31) 19 (34) 11 (27) 0.59
Biomarkers
Creatinine, mg/dl 1.1  0.6 1.2  0.7 1.0  0.4 0.17
eGFR, ml/min 58.7  19.3 56.6  20.9 61.9  16.8 0.26
NT-proBNP, ng/dl 4,771  7,397 4,882  6,448 4,602  8,755 0.47
Values are n (%) or mean  SD.
AbM ¼ abnormal multimer; eGFR ¼ estimated glomerular ﬁltration rate; GI ¼ gastrointestinal;
LVEF ¼ left ventricular ejection fraction; NM ¼ normal multimer; NT-proBNP ¼ N-terminal
pro–B-type natriuretic peptide; TTE ¼ transthoracic echocardiography.
FIGURE 2 High-Molecular-Weight Multimer Disparity
Differentiation of abnormal multimers (AbM) and normal
multimer (NM) patients by high-molecular-weight multimers
(HMWM).
FIGURE 1 Multimer Analysis and Quantiﬁcation
Exemplary illustration of the multimer analysis by gel electrophoresis and
quantitative densitometry. HMWM ¼ high-molecular-weight multimer;
LMWM ¼ low-molecular-weight multimer; MMWM ¼ medium-molecular-
weight multimer.
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694was measured by chemiluminescence immunoassay
(e411; Roche Diagnostics GmbH, Grenzach-Wyhlen,
Germany). Estimated glomerular ﬁltration rate was
calculated by CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) formula.
SPECIFIC BLOOD COLLECTION AND LABORATORY
ASSAYS. Hemostaseologic data was gathered and
analyzed before 1 day after, and 1 week after TAVR.
Multimer analysis was performed as described before
(19) in gels of low (1.2%) and medium resolution
(1.6%; LGT agarose type VII, Sigma, Munich,
Germany). Plasma samples were classiﬁed as eitherFIGURE 3 High-Molecular-Weight Multimer Course
40
30
20
10
0
pre 1 Day 1 Week
AbM
NM
H
M
W
M
 (%
)
Change of high-molecular-weight multimers (HMWM) in
abnormal multimer (AbM) and normal multimer (NM) patients
over time. Abbreviations as in Figure 2.
FIGURE 4 Correlation of dPmean to High-Molecular-Weight
Multimer
Connection of high-molecular-weight multimers (HMWM) to
mean transvalvular gradient (dPmean) in the study population.
Abbreviations as in Figure 2.
FIGURE 6 High-Molecular-Weight Multimer Alteration
and PVL
Change in high-molecular-weight multimer (HMWM) content
relative to paravalvular leakage after transcatheter aortic valve
replacement. PVL ¼ paravalvular leakage. Abbreviations as in
Figure 2.
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695abnormal multimers (AbM) or normal multimers (NM)
by comparison with the reference plasma (pool of
50 human control subjects). AbM were deﬁned as
a deviation from a normal distribution; either loss
of HMWM or presence of larger than normal (supra-
normal) multimers on low-resolution gels or as ab-
normal migration of individual oligomers or abnormal
separation into triplets/quintuplets on medium reso-
lution gels (Figure 1). Quantitative, densitometric gel
analysis was performed using software provided with
the video-detection system (AlphaEaseFC Stand
Alone software, Alpha Innotech Corp., San Leandro,
California). Samples with the same quantity of
VWF:Ag (von Willebrand factor antigen) were appliedFIGURE 5 Pressure Drop-Related High-Molecular-Weight Multimer
High-molecular-weight multimer (HMWM) increase following transcathe
abnormal multimer and normal multimer (NM) groups. dPmean ¼ meanto the gels. Because VWF function is strictly depen-
dent on it’s content of large multimers, a quantitative
evaluation of the multimer content was performed.
Small, intermediate, and large multimers were de-
ﬁned as oligomers 1 to 5, 6 to 10, and >10, respec-
tively, and evaluated by densitometry. In a survey
from the Scientiﬁc Subcommittee on VWF, in
32 laboratories worldwide (19) it turned out that
every laboratory used a different multimer method.
Therefore, multimer results from different labora-
tories are not directly comparable and there is no
normal reference range for the large multimer con-
tent. Our multimer method was validated from
January 2011 to August 2011 (validation is ongoing
for long-term stability). During the study period of
300 low-resolution gels were analyzed quantita-
tively. According to these results, an area under
the curve of less than 20.4% for the large multimersAlteration
ter aortic valve replacement relative to reduction of mean transvalvular gradient for the
transvalvular gradient. Abbreviations as in Figure 2.
TABLE 2 Baseline and End-Procedural Invasive Hemodynamic Data
Total
(n ¼ 95)
NM
(n ¼ 55)
AbM
(n ¼ 40) p Values
Valve oriﬁce area, cm2 p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 0.7  0.2 0.8  0.2 0.6  0.2 0.008
After TAVR 2.5  0.7 2.6  0.8 2.5  0.7 0.57
Valve oriﬁce area
index, cm/m2
p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 0.4  0.1 0.4  0.1 0.3  0.1 <0.0001
After TAVR 1.4  4.2 1.4  0.4 1.4  0.4 0.57
Cardiac output,
ml/min
p ¼ 0.002 p ¼ 0.06 p ¼ 0.01
Before TAVR 4.3  1.3 4.3  1.3 4.4  1.2 0.76
After TAVR 4.7  1.4 4.6  1.5 4.8  1.4 0.58
Cardiac index,
ml/min/m2
p ¼ 0.003 p ¼ 0.12 p ¼ 0.008
Before TAVR 2.4  0.6 2.3  0.6 2.5  0.6 0.33
After TAVR 2.6  0.7 2.5  0.7 2.7  0.8 0.18
Cardiac power
index, W/m2
p < 0.0001 p ¼ 0.0001 p ¼ 0.0002
Before TAVR 0.3  0.1 0.3  0.1 0.3  0.1 0.42
After TAVR 0.4  0.1 0.4  0.1 0.4  0.1 0.44
Stroke volume, ml p ¼ 0.060 p ¼ 0.13 p ¼ 0.33
Before TAVR 71.8  23.7 70.2  23.1 73.9  24.9 0.99
After TAVR 76.6  23.3 76.2  23.0 76.1  23.5 0.95
Stroke volume
index, ml/m2
p ¼ 0.076 p ¼ 0.10 p ¼ 0.40
Before TAVR 39.9  12.2 38.4  12.1 42.1  12.0 0.36
After TAVR 42.5  12.1 41.8  11.9 43.6  12.6 0.55
Zva, mm Hg*ml*m2 p ¼ 0.0006 p ¼ 0.055 p ¼ 0.002
Before TAVR 4.4  3.3 4.6  4.1 4.1  1.4 0.72
After TAVR 3.6  1.2 3.7  1.3 3.4  1.2 0.19
SAC, ml/m2/mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 1.2  0.6 1.2  0.5 1.4  0.7 0.47
After TAVR 0.9  0.4 0.9  0.3 1.0  0.5 0.40
PCWPmean, mm Hg p # 0.0001 p ¼ 0.0011 p ¼ 0.13
Before TAVR 16.7  6.0 17.6  7.0 16.3  6.0 0.36
After TAVR 19.6  8.1 20.6  8.3 18.2  7.6 0.17
SVRI, dyn*s*m2cm5 p ¼ 0.096 p ¼ 0.12 p ¼ 0.47
Before TAVR 2214  1080 2277  1268 2124  745.0 0.90
After TAVR 2332  907.5 2430  1030 2193  688.0 0.23
PASP, mm Hg p ¼ 0.01 p ¼ 0.0088 p ¼ 0.64
Before TAVR 43.4  12.6 43.8  12.7 42.7  12.6 0.69
After TAVR 46.3  14.8 47.3  14.4 44.9  13.8 0.48
PADP, mm Hg p ¼ 0.046 p ¼ 0.078 p ¼ 0.351
Before TAVR 16.6  7.2 17.0  6.4 16.1  8.3 0.15
After TAVR 17.8  7.3 18.5  7.4 16.7  7.2 0.24
PAMP, mm Hg p ¼ 0.014 p ¼ 0.015 p ¼ 0.567
Before TAVR 27.1  9.8 27.2  7.9 27.0  12.2 0.35
After TAVR 28.6  9.6 29.5  9.9 27.2  9.1 0.32
PVRI, dyn*s*m2cm5 p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 127.2  136.7 120.1  88.1 137.2  185.8 0.56
After TAVR 291.4  248.8 305.6  272.5 271.3  212.7 0.64
LVESP, mm Hg p < 0.0001 p ¼ 0.066 p < 0.0001
Before TAVR 156.1  33.0 146.1  28.4 170.2  34.2 0.0008
After TAVR 138.4  23.8 139.6  24.7 136.7  22.6 0.72
Continued on the next page
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The validity of our multimer method was reassured by
comparison of the multimer pattern of an ADAMTS13
digested recombinant VWF sample and a plasma
sample from a type 2A patient with our gel method and
the carrier free method ﬂuorescence correlation spec-
troscopy (20). The VWF:Ag was determined by a
sandwich enzyme-linked immunosorbent assay with
polyclonal antibodies as described (21).
STATISTICAL ANALYSIS. Continuous data were
described as means and standard deviations. Differ-
ences of metric variables between 2 groups were
analyzed with Student t tests, if the data were
approximately normally distributed, and with Mann-
Whitney test otherwise. Differences between 3
groups/sequential measurements were analyzed by
analysis of variance for normally distributed data and
the Kruskal-Wallis test otherwise with GraphPad
Prism (GraphPad Software Inc., San Diego, Califor-
nia). Categorical data were described with absolute
and relative frequencies. Differences between cate-
gorical variables were evaluated with the Fisher’s
exact test. In the case that the overall tests for group
effects were signiﬁcant, 2 group comparisons were
performed using the multiple comparison adjustment
of Bonferroni. Linear regression analysis was used to
investigate the interrelationship of HMWM and he-
modynamic variables. All p values are 2-sided. For
overall tests p # 0.05 was considered signiﬁcant and
for multiple comparisons Bonferroni-adjusted signif-
icance levels were used.
RESULTS
BASELINE DATA. We included 36 male and 59 female
subjects with a mean of 82.4  6.5 years of age
(Table 1). Comorbidities were dominated by hyper-
tension (93%) and coronary artery disease (57%).
Invasive dPmean averaged 43.7  17.7 mm Hg with an
echocardiographic mean left ventricular ejection
fraction of 54.9  11.2% and a pre-implantation CO of
4.3  1.3 l/min.
PROCEDURAL SUCCESS. Acute device success was
achieved in 89% of the patients. No patient was lost
during TAVR or in need of conversion to SAVR,
though 1 patient converted to transapical implanta-
tion. Twenty-two patients experienced a para-
valvular leakage $2 and 4 from a moderate but none
from a severe prosthesis-patient mismatch (PPM) at
the end of the procedure. PPM was considered if
the effective oriﬁce area indexed to the patient’s body
surface area was <0.85 cm2/m2 (moderate) or <0.65
cm2/m2 (severe) (22,23).
TABLE 2 Continued
Total
(n ¼ 95)
NM
(n ¼ 55)
AbM
(n ¼ 40) p Values
LVEDP, mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 12.4  6.7 12.9  6.4 11.9  7.2 0.50
After TAVR 16.6  7.8 16.5  7.4 16.9  8.4 0.98
AoPsys, mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 110.5  22.0 112.3  24.9 108.1  17.3 0.57
After TAVR 135.7  24.3 138.0  25.2 132.7  23.1 0.36
AoPdias, mm Hg p ¼ 0.005 p ¼ 0.061 p ¼ 0.029
Before TAVR 49.7  9.9 49.4  10.7 50.1  8.7 0.55
After TAVR 53.0  10.6 52.8  11.7 53.3  9.2 0.96
AoPmean, mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 71.1  12.7 71.7  14.4 70.4  10.0 0.76
After TAVR 81.3  13.5 82.2  14.8 80.1  11.7 0.40
dPmax, mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 47.6  27.2 36.5  21.0 62.8  27.2 <0.0001
After TAVR 3.5  3.6 3.2  2.4 4.2  4.8 0.62
dPmean, mm Hg p < 0.0001 p < 0.0001 p < 0.0001
Before TAVR 43.7  17.7 36.0  12.4 54.3  18.6 <0.0001
After TAVR 6.4  4.0 6.2  3.9 6.7  4.1 0.51
Aortic regurgitation
index (32)
26.2  8.3 26.0  9.9 26.3.  8.1 0.89
AoPdias¼ diastolic aortic pressure; AoPmean¼mean aortic pressure; AoPsys¼ systolic aortic pressure; dPmax¼
maximal transvalvular gradient; dPmean ¼ mean transvalvular gradient; LVEDP ¼ left ventricular end-diastolic
pressure; LVESP ¼ left ventricular end-systolic pressure; PADP ¼ pulmonary artery diastolic pressure; PAMP ¼
pulmonary artery mean pressure; PASP ¼ pulmonary artery systolic pressure; PCWPmean ¼ mean pulmonary
capillary wedge pressure; PVRI ¼ pulmonary vascular resistance index; SAC ¼ systemic arterial compliance;
SVRI ¼ systemic vascular resistance index; TAVR ¼ transcatheter aortic valve replacement; Zva ¼ valvuloarterial
impedance; other abbreviations as in Table 1.
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697Periprocedural complications according to VARC-2
criteria were documented in 10 patients, 4 of which
experienced a major stroke within 48 h. Eleven
patients needed a permanent pacemaker due to
conduction disturbances.
HEMOSTASEOLOGY AND TRANSVALVULAR HEMO-
DYNAMICS. Deﬁned by a densitometric HMWM con-
tent of <20.4% (24) we identiﬁed AbM in 42% of our
patients. By means of multimer analysis we measured
a HMWM content (% area under the curve) of 21.8 6.1
before implantation, 27.2  5.8 on day 1, and 25.3  5.7
after 1 week in the entire study population. An addi-
tional evaluation of VWF:Ag (collagen-binding assay),
VWF:CB, and GpIbM unveiled no further insights (25).
The AbM group had an average HMWM content of 16.2
 3.3% before implantation, whereas the NM group
presented with signiﬁcantly higher values (25.9 
4.0%; p < 0.0001) (Figure 2). Though normal by then,
the HMWM content remained distinctively lower in
AbM patients 1 day (25.4  5.8 vs. 28.5  5.4; p ¼ 0.02)
and 1 week after TAVR compared to the NM group
(23.6  5.0 vs. 26.7  5.8; p ¼ 0.008) (Figure 3). Only 3
patients of the AbM group did not recover their
HMWM after 1 week (HMWM 16.5  0.5). However, the
relative increase in HMWMwas signiﬁcantly greater in
AbM patients (mean difference [95% conﬁdence
interval]: 9.51 [6.86 to 12.17] vs. 2.52 [0.10 to 4.94]).
And contrary to the NM group, AbM patients also
possessed a signiﬁcantly higher HMWM content 1
week after implantation compared to their baseline
(7.65 [5.00 to 10.31] vs. 0.81 [–1.59 to 3.22]). Measure-
ments of dPmean pre-implantation were strongly
correlated with HMWM content (Figure 4) and corre-
lation slightly favored invasive pressure readings
(noninvasive: r ¼ –0.56; p < 0.0001; invasive: r ¼
–0.63; p < 0.0001). The dPmean of patients with AbM
was signiﬁcantly higher (54.3  18.6 mm Hg vs. 36.0 
12.4 mm Hg; p # 0.0001). The drop in dPmean after
TAVR correlated signiﬁcantly with the increase of
HMWM in patients with AbM (r ¼ 0.417; 95% conﬁ-
dence interval [CI]: 0.107 to 0.653; p ¼ 0.008), which it
did not in the NM group (r ¼ 0.128; 95% CI: –0.152
to 0.389; p ¼ 0.356) (Figure 5). Two patients of
the entire population had a signiﬁcant paravalvular
leak (PVL >2) after TAVR and their HMWM content
declined within a week. However, HMWM increased
signiﬁcantly if PVL was <2 (p ¼ 0.005, n ¼ 73) or 2 (p ¼
0.0001, n ¼ 20) (Figure 6). Furthermore, the correla-
tion of ARI in patients with PVL $2 revealed a
borderline signiﬁcance (r ¼ –0.4316; p ¼ 0.050).
HEMODYNAMICS. Hemodynamic data is presented
in Table 2. Pre-implantation LVESP (p < 0.0001),
dPmean (p < 0.0001), and dPmax (p < 0.0001) weresigniﬁcantly higher in patients with AbM compared to
the NM group. Baseline systemic arterial pressures,
pulmonary pressures, PCWP, CO, cardiac index, and
SAC were similar in both groups. This also applied
for Zva, pulmonary vascular resistance index, and
transpulmonary gradient before implantation. After
TAVR, the overall study population showed a signif-
icant increase in CO, cardiac index, and aortic pres-
sures. Furthermore, we observed a signiﬁcant
increase in PCWP and pulmonary artery pressures
as well as left ventricular end-diastolic pressure.
Otherwise, there was a decrease in Zva, SAC, trans-
valvular gradients, and LVESP after TAVR in both
groups. Post-procedural systemic arterial pressures,
pulmonary pressures, PCWP, CO, cardiac index, SAC,
and aortic regurgitation index again were similar in
both groups. PCWP and pulmonary artery pressures
remained unchanged only in the AbM group. Addi-
tionally, the drop in LVESP and increase in cardiac
index after TAVR was distinctive in the AbM group.
POST-IMPLANTATION THROMBOCYTOPENIA. Platelet
counts dropped by 27% after TAVR (169.3  78.8 to
126.0  56.7) but recovered within the following week
(157.7  74.0) without differences between the AbM and
NM groups. For further evaluation of the post-
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levels were measured by enzyme-linked immunosor-
bent assay, but found to be within normal limits in all
patients and at all time points (data not shown).
BLEEDING, TRANSFUSION, AND OUTCOMES. Review
of clinical records and patient history revealed 18%
of our patients have had bleeding episodes before
TAVR. Gastrointestinal bleeding was registered in 11%
of the patients, with endoscopically veriﬁed angio-
dysplasias as the cause in 3 patients. Three patients
where found to experience gastrointestinal bleeding
and AbM denoting Heyde’s syndrome in 7.5% of the
patients with AbM. Periprocedurally our patients
received 1.7  3.6 packed red blood concentrate
(PRBC) without signiﬁcant difference in between
groups (p ¼ 0.55). Nevertheless, patients that were
deceased within the ﬁrst year received signiﬁcantly
more PRBC (6.6  7.3 vs. 1.2  2.8; p < 0.0001). Life-
threatening or disabling bleeding (VARC-2) occurred
in 3 of our patients as a result of access site compli-
cation. One of them belonged to the AbM 2 to the NM
group of which 1 died within 30 days. Major vascular
complications other than bleedings were encountered
in 2 patients and necessitated 17% of the PRBC that
were transfused in all patients. One of them was
deceased within 30 days, none experienced AbM.
Thirty-day mortality was 4.2% and 8 patients (8.4%)
died within the ﬁrst year after TAVR.
DISCUSSION
Deﬁciency of the HMWM and/or AbM are known to
facilitate bleeding if not leading to Heyde’s syndrome
(2). SAVR has been proven to correct factor deﬁciency
(5,7) and treat bleeding episodes in patients with AS
(26). Nevertheless, this approach is not without risk,
as SAVR does require ample access and cardiopul-
monary bypass with substantial doses of heparin. And
though in this context the minimally invasive TAVR
without cardiopulmonary bypass may be advanta-
geous in patients with a bleeding diathesis, little is
known about the impact on von Willebrand multi-
mers and aVWS in the TAVR population.
We discovered 42% of our patients to experience
AbM with an average HMWM content of 16.2  3.3%.
This ﬁnding is in line with smaller investigations in
patients undergoing SAVR (5,6,27), but to the best of
our knowledge for the ﬁrst time provides data on a
larger scale for patients undergoing femoral TAVR.
After TAVR, 90%of the patientswith AbMpresented
with a normal multimer distribution and densitom-
etry. And although these patients signiﬁcantly
increased in HMWM content compared to baseline, thepatients with NM did not (Figure 3). TAVR not only led
to a normalization of HMWM content in patients with
prior AbM, it also left HMWM in the remainder of the
study population unaltered. Thus denoting peri-
procedural secretion implausible.
Condensing the hemostaseologic and hemodynamic
ﬁndings disclosed further information. Correlation of
HMWM count to dPmean in our population (r ¼ –0.63;
p < 0.0001) matches previous reports (r ¼ –0.76; p <
0.001; and r ¼ –0.56; p < 0.001) (6,27). However, 2 pa-
tients experienced a PVL >2þ after TAVR and their
HMWM content declined substantially within a week
whereas the HMWM of patients with AR/PVL<2
increased instead (p ¼ 0.003). Also, all 4 patients that
did not recover from their AbM experienced mild-
moderate AR/PVL after TAVR. Appropriately enough,
the correlation of ARI to HMWM in patients with
PVL $2 after TAVR was borderline signiﬁcant (–0.4316;
p ¼ 0.050). Indistinguishable by HMWM, however,
PPM occurred in 4% of the patients. Thus, compared to
SAVR (up to 20%) PPM is rare and does not seem to
have the same bearing. In conclusion, and as they are
reciprocally affected by the transvalvular gradient,
HMWM can be proposed as a (hemostaseologic) marker
of the severity of aortic valvular stenosis. These results,
moreover, emphasize persistent and recurrent shear
stress as the cause of multimer deﬁciency. Because AR/
PVL after TAVR is associated with mortality (28),
HMWM quantiﬁcation could theoretically serve as a
prognostic biomarker once a consensus on the cutoff
(% area under the curve) is established. Future studies
are needed to clarify whether HMWM and their quan-
titative analysis in low-resolution gels can perform as
an adjunct to established grading systems.
Patients with AbM presented with signiﬁcantly
higher transvalvular pressure gradients and LVESP.
The valve oriﬁce area was signiﬁcantly smaller
(Table 2). A pertinent ﬁnding in view of a presumably
shear stress–induced genesis of the aVWS. Signiﬁcant
increase of cardiac index in the AbM patients and
their lower Zva with its prognostic capabilities (29)
probably identify AbM patients as more severely
obstructed and particularly appreciative for TAVR.
Because severe aVWS (i.e., low content of HMWM
and bleeding episodes) as well as prior bleeding epi-
sodes have been associated with excessive bleeding/
transfusion needs in patients undergoing SAVR (6) we
examined the rate of transfusion and bleeding. The
incidence of PRBC transfusion in our study was 37%
including 30 days after TAVR. In contrast, SAVR
without blood conservation strategy has recently
been assigned a transfusion rate of 82.9% and with
blood conservation strategy 68% of the patients still
needed transfusion (30). Although we observed a
PERSPECTIVES
Deﬁciency of HMWM and/or AbM are known to facilitate
bleeding, if not leading to Heyde’s syndrome, in patients with
aortic stenosis and SAVR having been proven to correct this
deﬁciency. Although transcatheter aortic valve replacement
leads to a normalization of HMWM content in patients with prior
AbM (42%), residual aortic regurgitation/leakage leads to infe-
rior HMWM recovery. As HMWM content is strongly correlated
with mean transvalvular gradient and aortic regurgitation results
in inferior factor recovery, future studies need to determine
whether HMWM content is capable of distinguishing between
groups with discriminable prognostic properties or could act as a
biomarker for procedural success.
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699rather high incidence of transfusion for TAVR, the
quantity did not differ in between patients belonging
to the AbM and the NM group and it was nearly one-
half of what patients undergoing SAVR with blood
conservation strategy required lately (1.7  3.6 PRBC/
patient vs. 2.9  4.3 PRBC/patient) (30). Bleeding
under TAVR being unaffected by an AbM distri-
bution might be explained by the fact that it was ac-
cess site related and rather caused by anatomical than
hemostatic elements. In contrary, wound surfaces
and drainage sites of SAVR are understandably sub-
ject to an aVWS or AbM. Narrowing the view to the
well-known transfusion-associated increase in mor-
tality, these ﬁndings argue in favor of TAVR for pa-
tients with AbM or aVWS.
STUDY LIMITATIONS. This single-center study com-
bines 4 different devices for TAVR and whether the
correlational data is applicable to other collectives
remains uncertain. Prior bleeding episodes were
incompletely detected because we did not use a
bleeding questionnaire and owed to the fact that
spontaneous bleeding is rather infrequent among
aVWS patients. Finally, blood sampling during a long-
term follow-up would have been of additional value.
CONCLUSIONS
We describe a signiﬁcant prevalence of AbM in
patients with AS undergoing TAVR, and a close rela-
tionship of transvalvular pressure gradients and the
extent of HMWM deﬁciency. And although an ex-
cellent correction of hemostaseologic as well as he-
modynamic pathology takes place, about one-half the
rate of transfusions compared to SAVR are needed.
And opposed to SAVR, there was no increase in
bleeding or transfusion needs in patients with severe
VWF deﬁciency undergoing TAVR. We hypothesize
this to be reasoned by the fact that severe bleeding in
our population involved access site complications
and was not attributable to large wound surfaces as in
SAVR patients. Therefore, bleeding and transfusion is
not as conditional to factor deﬁciencies and AbM
therefore does not bring about the same undesirableconsequences in TAVR. Moreover, the intervention
itself does not adversely affect beforehand normal
HMWM, whereas extracorporeal life support as car-
diopulmonary bypass is known to consume HMWM
(31), probably even more so in patients with aVWS,
who have been shown to be at an increased risk of
bleeding/transfusion with SAVR. In view of the min-
imal invasive, less sanguineous but hemostaseologic
proﬁcient approach, TAVR deserves consideration as
the primary approach for patients with severe aVWS
or AbM. But in view of the signiﬁcant correlation of
dPmean decrease with HMWM increase as well as
recurrence of factor deﬁciency in patients with AR/
PVL, HMWM seem to reach beyond and our study
exposes HMWM content as a marker of shear stress
and therefore stenosis severity. Whether HMWM
content is capable of distinguishing between groups
with discriminable prognostic properties or could act
as a biomarker for procedural success remains to be
proven by future investigations.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Tobias Spangenberg, Asklepios Klinik St. Georg,
Department of Cardiology, Lohmuehlenstrasse 5,
20099 Hamburg, Germany. E-mail: t.spangenberg@
asklepios.com.RE F E RENCE S1. Warkentin TE, Moore JC, Anand SS, Lonn EM,
Morgan DG. Gastrointestinal bleeding, angiodys-
plasia, cardiovascular disease, and acquired von
Willebrand syndrome. Transfus Med Rev 2003;17:
272–86.
2. Warkentin TE, Moore JC, Morgan DG. Aortic
stenosis and bleeding gastrointestinal angiodys-
plasia: is acquired von Willebrand’s disease the
link? Lancet 1992;340:35–7.3. Heyde E. Gastrointestinal bleeding in aortic
stenosis. N Engl J Med 1958;259.
4. Le Tourneau T, Susen S, Caron C, et al. Functional
impairment of von Willebrand factor in hypertrophic
cardiomyopathy: relation to rest and exercise
obstruction. Circulation 2008;118:1550–7.
5. Panzer S, Badr Eslam R, Schneller A, et al. Loss
of high-molecular-weight von Willebrand factor
multimers mainly affects platelet aggregation inpatients with aortic stenosis. Thromb Haemost
2010;103:408–14.
6. Vincentelli A, Susen S, Le Tourneau T, et al.
Acquired von Willebrand syndrome in aortic ste-
nosis. N Engl J Med 2003;349:343–9.
7. Thompson JL 3rd, Schaff HV,Dearani JA, et al. Risk
of recurrent gastrointestinal bleeding after aortic
valve replacement in patients with Heyde syndrome.
J Thorac Cardiovasc Surg 2012;144:112–6.
Spangenberg et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 5 , 2 0 1 5
von Willebrand Multimers and TAVR A P R I L 2 7 , 2 0 1 5 : 6 9 2 – 7 0 0
7008. Smith CR, Leon MB, Mack MJ, et al. Trans-
catheter versus surgical aortic-valve replacement
in high-risk patients. N Engl J Med 2011;364:
2187–98.
9. Adams DH, Popma JJ, Reardon MJ, et al.
Transcatheter aortic-valve replacement with a
self-expanding prosthesis. N Engl J Med 2014;
370:1790–8.
10. Lynch DR Jr., Dantzler D, Robbins M, Zhao D.
Considerations in antithrombotic therapy among
patients undergoing transcatheter aortic valve im-
plantation. J ThrombThrombolysis 2013;35:476–82.
11. Ribeiro HB, Urena M, Kuck KH, Webb JG,
Rodes-Cabau J. Edwards CENTERA valve. Euro-
Intervention 2012;8 Suppl Q:Q79–82.
12. Binder RK, Schafer U, Kuck KH, et al.
Transcatheter aortic valve replacement with a new
self-expanding transcatheter heart valve and
motorized delivery system. J Am Coll Cardiol Intv
2013;6:301–7.
13. Grube E, Schuler G, Buellesfeld L, et al.
Percutaneous aortic valve replacement for severe
aortic stenosis in high-risk patients using the
second- and current third-generation self-
expanding CoreValve prosthesis: device success
and 30-day clinical outcome. J Am Coll Cardiol
2007;50:69–76.
14. Webb JG, Chandavimol M, Thompson CR, et al.
Percutaneous aortic valve implantation retrograde
from the femoral artery. Circulation 2006;113:
842–50.
15. Chambers JB, Sprigings DC, Cochrane T,
et al. Continuity equation and Gorlin formula
compared with directly observed oriﬁce area in
native and prosthetic aortic valves. Br Heart J
1992;67:193–9.
16. Gorlin R, Gorlin SG. Hydraulic formula for
calculation of the area of the stenotic mitral valve,other cardiac valves, and central circulatory
shunts. I. Am Heart J 1951;41:1–29.
17. Chemla D, Hebert JL, Coirault C, et al. Total
arterial compliance estimated by stroke volume-
to-aortic pulse pressure ratio in humans. Am J
Physiol 1998;274:H500–5.
18. Kappetein AP, Head SJ, Genereux P, et al.
Updated standardized endpoint deﬁnitions for
transcatheter aortic valve implantation: the Valve
Academic Research Consortium-2 consensus
document. J Thorac Cardiovasc Surg 2013;145:
6–23.
19. Lee CA, Hubbard A, Sabin CA, et al. Laboratory
diagnosis of von Willebrand disease: results from a
prospective and blind study in 32 laboratories
worldwide using lyophilized plasmas. J Thromb
Haemost 2011;9:220–2.
20. Lippok S, Obser T, Muller JP, et al. Exponential
size distribution of von Willebrand factor. Biophys
J 2013;105:1208–16.
21. Cejka J. Enzyme immunoassay for factor VIII-
related antigen. Clin Chem 1982;28:1356–8.
22. Rahimtoola SH. The problem of valve
prosthesis-patient mismatch. Circulation 1978;58:
20–4.
23. Pibarot P, Dumesnil JG. Prosthesis-patient
mismatch: deﬁnition, clinical impact, and preven-
tion. Heart 2006;92:1022–9.
24. BuddeU, SchneppenheimR, EikenboomJ, et al.
Detailed vonWillebrand factor multimer analysis in
patients with von Willebrand disease in the Euro-
pean study, molecular and clinical markers for the
diagnosis and management of type 1 von Wille-
brand disease (MCMDM-1VWD). J ThrombHaemost
2008;6:762–71.
25. Sucker C, Feindt P, Zotz RB, Stockschlaeder M,
Scharf RE. Functional von Willebrand Factor as-
says are not predictive for the absence of highest-molecular weight von Willebrand Factor multimers
in patients with aortic-valve stenosis. Thromb
Haemost 2005;94:465–6.
26. King RM, Pluth JR, Giuliani ER. The association
of unexplained gastrointestinal bleeding with
calciﬁc aortic stenosis. Ann Thorac Surg 1987;44:
514–6.
27. Blackshear JL, Wysokinska EM, Safford RE,
et al. Indexes of von Willebrand factor as bio-
markers of aortic stenosis severity (from the Bio-
markers of Aortic Stenosis Severity [BASS] study).
Am J Cardiol 2013;111:374–81.
28. Kodali SK, Williams MR, Smith CR, et al. Two-
year outcomes after transcatheter or surgical
aortic-valve replacement. N Engl J Med 2012;366:
1686–95.
29. Lancellotti P, Donal E, Magne J, et al. Risk
stratiﬁcation in asymptomatic moderate to severe
aortic stenosis: the importance of the valvular,
arterial and ventricular interplay. Heart 2010;96:
1364–71.
30. Yaffee DW, Smith DE 3rd, Ursomanno PA,
et al. Management of blood transfusion in aortic
valve surgery: impact of a blood conservation
strategy. Ann Thorac Surg 2014;97:95–101.
31. Heilmann C, Geisen U, Beyersdorf F, et al.
Acquired von Willebrand syndrome in patients
with extracorporeal life support (ECLS). Intensive
Care Med 2012;38:62–8.
32. Sinning JM, Hammerstingl C, Vasa-Nicotera M,
et al. Aortic regurgitation index deﬁnes severity
of peri-prosthetic regurgitation and predicts out-
come in patients after transcatheter aortic valve
implantation. J Am Coll Cardiol 2012;59:1134–41.KEY WORDS aortic stenosis,
transcatheter aortic valve replacement,
von Willebrand syndrome
